Xolair 150 MG/ML autoinjectorml
Ended Awarded
- Contract number
- SPE2DB26FDQDX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,568
Award facts
- Contract value 100% obligated
- $2,568.33 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,568.33 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml autoinjectors, with an ultimate completion date of November 18, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. This delivery order represents one of numerous purchases issued to the vendor under its broader indefinite delivery contract with the Defense Logistics Agency.
This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply chains for Department of Defense healthcare facilities worldwide. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for branded and generic pharmaceuticals, biologics, and medical consumables to support military medical operations globally. DMS Pharmaceutical Group's established performance across multiple delivery orders covering diverse therapeutic categories, including specialty pharmaceuticals and biologics, positions the company as a critical supplier within the federal military healthcare supply chain.
Quick answers
Who was awarded contract SPE2DB26FDQDX?
SPE2DB26FDQDX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FDQDX worth?
The government has obligated $2,568 on SPE2DB26FDQDX.
Is contract SPE2DB26FDQDX an order under another contract?
Yes. SPE2DB26FDQDX is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDX competed?
The extent of competition for SPE2DB26FDQDX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award